Rescop Opens New Offices in the United Kingdom and Australia
Rescop announced today the opening of their offices in the UK and Australia.
Rescop (Regulatory System Compliance Partners), an international life sciences service and solution provider, announced today the opening of their offices in the U.K. and Australia. Following the opening of offices in Belgium and the USA in 2013, the opening of these new offices is a next step as part of the internationalization strategy of Rescop, in order to serve their clients globally.
Piet Vervoort, Rescop’s Managing Director, said:
“We’re excited to expand our activities in the U.K. and Australia. The move was required to accommodate both our current and future growth in E.U. and the Asia Pacific area, as we continue to expand our team of Life Sciences and software development experts to meet the increasing demand for our consulting services and software products.”
Since its founding in 2005 by Piet Vervoort and Björn Aalbers, Rescop, with its headquarters in Den Bosch, has grown to 8 offices globally.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.
